#None #Drug Discovery #Pierre Fabre #RedRidge

Strategic Alliance in Drug Discovery: Pierre Fabre and RedRidge Bio

In a significant advancement in biopharmaceutical research, Pierre Fabre Laboratories and RedRidge Bio have announced a groundbreaking collaboration aimed at drug discovery and co-development. This exclusive agreement, unveiled on March 12, 2025, marks a strategic partnership prioritizing the development of biparatopic antibodies (BPAs) targeting various therapeutic needs, particularly in precision oncology, dermatology, and rare diseases.

This partnership is crucial as it aligns with Pierre Fabre's commitment to innovation and strengthens its already established programs in drug development. The collaboration seeks to identify and develop novel drug candidates that can efficiently target multiple indications, enhancing patient outcomes in critically underserved areas.

Under the terms of this collaboration, RedRidge will leverage its specialized know-how to engineer, screen, and characterize BPAs against a set of undisclosed joint targets. Pierre Fabre Laboratories will then take charge of advancing these discoveries through the full spectrum of clinical development phases. This unique arrangement ensures that both parties can effectively utilize their strengths: RedRidge's innovative approach to drug discovery combined with Pierre Fabre's extensive experience in drug development.

Notably, RedRidge has secured exclusive commercial rights in the United States, Canada, and Japan, while Pierre Fabre will retain rights for the rest of the world. This delineation allows both companies to operate within their respective market strengths, maximizing the potential for success across multiple territories. In addition to these allocations, Pierre Fabre will hold exclusive global rights for an additional program after it transitions to them from RedRidge at the preclinical stage.

Financial arrangements surrounding the partnership include undisclosed terms that encompass an investment from Pierre Fabre in RedRidge's Series A financing, alongside milestone payments, sales royalties, and funded research commitments related to Pierre Fabre's global rights. Both firms will also share research and development costs associated with the co-developed programs, ensuring mutual investment in the partnership's success.

Alex Mayweg, PhD, chairperson of RedRidge's board and managing director at Versant Ventures, expressed enthusiasm for the strategic alliance, stating, "This strategic alliance attests to the RedRidge team's expertise in innovation and drug discovery for a wide variety of therapeutic targets. We are thrilled to join forces with Pierre Fabre Laboratories as a highly experienced development partner and look forward to building a long-term partnership that synergistically leverages the capabilities of each company."

Francesco Hofmann, PhD, Head of Research and Development for Medical Care at Pierre Fabre Laboratories, reaffirmed the significance of this collaboration, remarking, "This partnership will allow us to capitalize on RedRidge's cutting-edge expertise in biparatopic antibody drug discovery to deliver high quality clinical candidates on multiple targets addressing oncology, dermatology, and rare diseases. It represents a significant milestone in the implementation of our strategy to enrich our RD pipeline further."

In conclusion, the partnership between Pierre Fabre Laboratories and RedRidge Bio highlights a burgeoning era of collaborative innovation in the biotech sector. As these two organizations embark on their joint journey, the potential for groundbreaking therapeutic solutions expands, paving the way for advances in treatment for some of the most challenging conditions facing patients today.